table of content
1 Study Coverage
1.1 Pharmaceutical CDMO Services Revenue in Pharmaceutical CDMO Services Business (2017-2022) & (US$ Million) Introduction
1.2 Global Pharmaceutical CDMO Services Outlook 2017 VS 2022 VS 2028
1.2.1 Global Pharmaceutical CDMO Services Market Size for the Year 2017-2028
1.2.2 Global Pharmaceutical CDMO Services Market Size for the Year 2017-2028
1.3 Pharmaceutical CDMO Services Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Pharmaceutical CDMO Services in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Pharmaceutical CDMO Services Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Pharmaceutical CDMO Services Market Dynamics
1.4.1 Pharmaceutical CDMO Services Industry Trends
1.4.2 Pharmaceutical CDMO Services Market Drivers
1.4.3 Pharmaceutical CDMO Services Market Challenges
1.4.4 Pharmaceutical CDMO Services Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Pharmaceutical CDMO Services by Type
2.1 Pharmaceutical CDMO Services Market Segment by Type
2.1.1 Drug Substance Development and Manufacturing
2.1.2 Specialized Services
2.1.3 Lab-based Services
2.2 Global Pharmaceutical CDMO Services Market Size by Type (2017, 2022 & 2028)
2.3 Global Pharmaceutical CDMO Services Market Size by Type (2017-2028)
2.4 United States Pharmaceutical CDMO Services Market Size by Type (2017, 2022 & 2028)
2.5 United States Pharmaceutical CDMO Services Market Size by Type (2017-2028)
3 Pharmaceutical CDMO Services by Application
3.1 Pharmaceutical CDMO Services Market Segment by Application
3.1.1 Innovative Medicine
3.1.2 Patented Drug
3.1.3 Patent Expired Drug
3.2 Global Pharmaceutical CDMO Services Market Size by Application (2017, 2022 & 2028)
3.3 Global Pharmaceutical CDMO Services Market Size by Application (2017-2028)
3.4 United States Pharmaceutical CDMO Services Market Size by Application (2017, 2022 & 2028)
3.5 United States Pharmaceutical CDMO Services Market Size by Application (2017-2028)
4 Global Pharmaceutical CDMO Services Competitor Landscape by Company
4.1 Global Pharmaceutical CDMO Services Market Size by Company
4.1.1 Top Global Pharmaceutical CDMO Services Companies Ranked by Revenue (2021)
4.1.2 Global Pharmaceutical CDMO Services Revenue by Player (2017-2022)
4.2 Global Pharmaceutical CDMO Services Concentration Ratio (CR)
4.2.1 Pharmaceutical CDMO Services Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Pharmaceutical CDMO Services in 2021
4.2.3 Global Pharmaceutical CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Pharmaceutical CDMO Services Headquarters, Revenue in Pharmaceutical CDMO Services Business (2017-2022) & (US$ Million) Type
4.3.1 Global Pharmaceutical CDMO Services Headquarters and Area Served
4.3.2 Global Pharmaceutical CDMO Services Companies Revenue in Pharmaceutical CDMO Services Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Pharmaceutical CDMO Services Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Pharmaceutical CDMO Services Market Size by Company
4.5.1 Top Pharmaceutical CDMO Services Players in United States, Ranked by Revenue (2021)
4.5.2 United States Pharmaceutical CDMO Services Revenue by Players (2020, 2021 & 2022)
5 Global Pharmaceutical CDMO Services Market Size by Region
5.1 Global Pharmaceutical CDMO Services Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Pharmaceutical CDMO Services Market Size by Region (2017-2028)
5.2.1 Global Pharmaceutical CDMO Services Market Size by Region: 2017-2022
5.2.2 Global Pharmaceutical CDMO Services Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Pharmaceutical CDMO Services Market Size YoY Growth 2017-2028
6.1.2 North America Pharmaceutical CDMO Services Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Pharmaceutical CDMO Services Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Pharmaceutical CDMO Services Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Pharmaceutical CDMO Services Market Size YoY Growth 2017-2028
6.3.2 Europe Pharmaceutical CDMO Services Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Pharmaceutical CDMO Services Market Size YoY Growth 2017-2028
6.4.2 Latin America Pharmaceutical CDMO Services Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Pharmaceutical CDMO Services Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Pharmaceutical CDMO Services Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Recipharm AB
7.1.1 Recipharm AB Company Details
7.1.2 Recipharm AB Business Overview
7.1.3 Recipharm AB Pharmaceutical CDMO Services Introduction
7.1.4 Recipharm AB Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.1.5 Recipharm AB Recent Development
7.2 AMRI Global
7.2.1 AMRI Global Company Details
7.2.2 AMRI Global Business Overview
7.2.3 AMRI Global Pharmaceutical CDMO Services Introduction
7.2.4 AMRI Global Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.2.5 AMRI Global Recent Development
7.3 Patheon N.V.
7.3.1 Patheon N.V. Company Details
7.3.2 Patheon N.V. Business Overview
7.3.3 Patheon N.V. Pharmaceutical CDMO Services Introduction
7.3.4 Patheon N.V. Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.3.5 Patheon N.V. Recent Development
7.4 Aenova Group
7.4.1 Aenova Group Company Details
7.4.2 Aenova Group Business Overview
7.4.3 Aenova Group Pharmaceutical CDMO Services Introduction
7.4.4 Aenova Group Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.4.5 Aenova Group Recent Development
7.5 Catalent, Inc.
7.5.1 Catalent, Inc. Company Details
7.5.2 Catalent, Inc. Business Overview
7.5.3 Catalent, Inc. Pharmaceutical CDMO Services Introduction
7.5.4 Catalent, Inc. Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.5.5 Catalent, Inc. Recent Development
7.6 Amatsigroup
7.6.1 Amatsigroup Company Details
7.6.2 Amatsigroup Business Overview
7.6.3 Amatsigroup Pharmaceutical CDMO Services Introduction
7.6.4 Amatsigroup Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.6.5 Amatsigroup Recent Development
7.7 WuXi AppTec Group
7.7.1 WuXi AppTec Group Company Details
7.7.2 WuXi AppTec Group Business Overview
7.7.3 WuXi AppTec Group Pharmaceutical CDMO Services Introduction
7.7.4 WuXi AppTec Group Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.7.5 WuXi AppTec Group Recent Development
7.8 Strides Pharma Science Limited
7.8.1 Strides Pharma Science Limited Company Details
7.8.2 Strides Pharma Science Limited Business Overview
7.8.3 Strides Pharma Science Limited Pharmaceutical CDMO Services Introduction
7.8.4 Strides Pharma Science Limited Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.8.5 Strides Pharma Science Limited Recent Development
7.9 Piramal Pharma Solutions
7.9.1 Piramal Pharma Solutions Company Details
7.9.2 Piramal Pharma Solutions Business Overview
7.9.3 Piramal Pharma Solutions Pharmaceutical CDMO Services Introduction
7.9.4 Piramal Pharma Solutions Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.9.5 Piramal Pharma Solutions Recent Development
7.10 Siegfried Ltd
7.10.1 Siegfried Ltd Company Details
7.10.2 Siegfried Ltd Business Overview
7.10.3 Siegfried Ltd Pharmaceutical CDMO Services Introduction
7.10.4 Siegfried Ltd Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.10.5 Siegfried Ltd Recent Development
7.11 Fareva Group
7.11.1 Fareva Group Company Details
7.11.2 Fareva Group Business Overview
7.11.3 Fareva Group Pharmaceutical CDMO Services Introduction
7.11.4 Fareva Group Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.11.5 Fareva Group Recent Development
7.12 FAMAR Health Care Services
7.12.1 FAMAR Health Care Services Company Details
7.12.2 FAMAR Health Care Services Business Overview
7.12.3 FAMAR Health Care Services Pharmaceutical CDMO Services Introduction
7.12.4 FAMAR Health Care Services Revenue in Pharmaceutical CDMO Services Business (2017-2022)
7.12.5 FAMAR Health Care Services Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
